POELLATH advises management of HiperScan on sale of the company to Fagron
The Dresden-based technology company HiperScan is a specialist in near-infrared (NIR) spectroscopy and emerged as a spin-off from the Fraunhofer Institute for Photonic Microsystems (IPMS) in 2006. With the Apo-Ident analysis system, which is specially designed to identify raw materials and is used in over 5,500 pharmacies, HiperScan has become a market leader in this segment in Germany. HiperScan currently employs more than 50 people.
Fagron is a global leader in pharmaceutical manufacturing of personalized medicines, focused on providing personalized medicine to hospitals, pharmacies, clinics and patients in 35 countries around the world.
As part of the Fagron family, Hiperscan can now establish its breakthrough material analysis technology on a global scale.
POELLATH advised the shareholder-managers of HiperScan GmbH with the following team:
- Dr. Michael Inhester (partner, lead, M&A, venture capital, Munich).
- Andreas Kühnert (counsel, co-lead, M&A, venture capital, Munich)
- Adalbert Makos (counsel, M&A, venture capital, Munich)
Contact
